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ABSTRACT
Objectives: The aim of this study was to evaluate the safety, feasibility, and effectiveness of transvaginal myomectomy surgery.
Material and methods: We conducted a retrospective study in Shengjing Hospital of China Medical University. In all, 
138 patients underwent transvaginal myomectomy from March 2009 to March 2019. The perioperative clinical data, such 
as position and size of myomas, operative duration, blood loss, intraoperative and postoperative complications, and hos-
pitalization time were retrospectively analyzed.
Results: All transvaginal myomectomies were performed without conversion to laparotomy. The mean vaginal operating 
time was 56.0 (± 17.2) minutes. The mean operative estimated blood loss was 89.2 (± 36.8) mL. No significant intraopera-
tive complications occurred. The median time of intestinal function recovery after operation was 1 day (range 1–4 days). 
The median time of hospital stay was 4 days (range 3–10 days); 12 (8.7%) patients experienced postoperative morbidity.
Conclusions: Transvaginal myomectomy is a minimally invasive surgery that can be performed without leaving a scar on 
the body surface. It can be performed safely and effectively by a skilled surgeon in cases with a specific surgical indication 
for this approach. 
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INTRODUCTION
Uterine fibroids are the most common benign tumors of 
the female reproductive organs, being found in 20–30% of 
women of reproductive age [1]. Leiomyoma is an important 
clinical condition in gynecology. It causes abnormal uterine 
bleeding, pelvic pressure symptoms, spontaneous abortion, 
and pelvic pain [2]. Most patients require surgical treatment 
for symptomatic fibroids. Since uterine fibroids are well-lined 
and non-capsulated benign tumors, myomectomy is 
an effective treatment option for symptomatic fibroids [3]. 
In recent years, with increased awareness of health care 
and greater requirements for quality of life, the incidence of 
myomectomy is increasing [4, 5]. In addition to the classical 
treatment strategy of laparotomy, other techniques such as 
laparoscopy, operative hysteroscopy and the transvaginal 
route have been widely used for uterine fibroids in recent 
decades [6]. The choice of approach for a myomectomy de-
pends on the size, number, and location of fibroids, as well as 
the skill of the surgeon. In 1994, Magos et al. [7] first reported 
3 cases of transvaginal myomectomy. Compared with lapa-
roscopy, transvaginal myomectomy is considered to offer 
many advantages, such as leaving no external scarring, low 
medical cost, and quick postoperative recovery. Being that 
it is less invasive than laparoscopy, there is also a better 
psychological outcome for the patient [8, 9]. However, due 
to limited operating space, a restricted field of view, and 
other relevant complications, the application of transvaginal 
myomectomy is not as widespread as that of laparoscopic 
surgery [10]. This paper retrospectively analyzed the clinical 
data, complications, and outcomes of a series of patients 
who underwent transvaginal myomectomy performed by 
experienced surgeons over the past 10 years. The goals of 
this study are to investigate the safety, feasibility, and ef-
fectiveness of this surgical procedure.
MATERIAL AND METHODS
Subjects
This study collected 138 cases of patients with complete 
medical records, who underwent transvaginal myomectomy 
in the Department of Obstetrics and Gynecology, Shengjing 
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Hospital of China Medical University from March 2009 to 
March 2019. The characteristics of the patients are reported 
in Table 1. All of the patients provided informed consent. This 
study was approved by the Ethics Committee of our hospital.
Preoperative assessments
In addition to a complete medical history, all patients 
underwent careful physical and ultrasound examinations 
to comprehensively evaluate the uterus and fibroids (size, 
location, morphology, and activity). Some patients also un-
derwent pelvic magnetic resonance imaging (MRI). Before 
transvaginal myomectomy, cervical cytology was routinely 
performed on all patients, and diagnostic curettage was 
performed on patients with abnormal menstruation to ex-
clude endometrial lesions. The preoperative examinations 
excluded the ovarian diseases, pelvic adhesions, severe 
endometriosis, or pelvic inflammation.
Preoperative preparation
Sexual activity was forbidden for all patients for one 
week before surgery, and iodophor was used for vaginal 
disinfection twice per day for three days before the surgery. 
If vaginal inflammation was present before surgery, trans-
vaginal myomectomy was not performed until the vaginal 
inflammation was cured. All patients underwent routine 
preoperative mechanical and chemical bowel preparation 
and received a single dose of prophylactic intravenous an-
tibiotics immediately before the start of the procedure. 
The procedure was performed under general endotracheal 
anesthesia in the lithotomy position.
Surgical procedure
If uterine fibroids were located in the posterior wall of 
the uterus, the posterior vaginal wall was incised at the 
uterosacral ligament to expose the pouch of Douglas and 
access the retroperitoneum. If uterine fibroids were located 
in the anterior wall of the uterus, an incision was made 
along the anterior fornix bilaterally and inwardly until the 
anterior peritoneum was reached. If the anterior wall space 
was limited, it was enlarged by an inverted “T” incision; 
if the uterus was large, the anterior and posterior fornices 
were incised simultaneously to enter the abdominal cavity, 
which is conducive to everting the uterus. After entering the 
abdomen, the location, size, and number of fibroids were 
explored. The uterus and uterine fibroids were exposed, 
and the fibroids were clamped and pulled outward. Pituitrin 
(6–12 U) was injected into the myometrium in the vicinity 
of the tumor. The myometrium was bisected to the fibroid 
pseudocapsule, and uterine fibroids were dissected. If a fi-
broid was large and could not be completely removed via 
the vagina, it was separated while being morcellated into 
wedge-shaped pieces, so it could be removed via the va-
gina. After the removal of larger fibroids, the whole uterine 
body was pulled into the vagina. Careful examination was 
undertaken by the surgeon of the uterine body for small 
fibroids, which were removed if present. The fibroid pseu-
docapsule was trimmed using 1–0 absorbable sutures to 
suture the uterus with intermittent sutures of 1 to 2 layers 
of the myometrium and continuous suturing of the serosa 
layer. Subsequently, 2–0 absorbable sutures were used to 
suture the peritoneal reflection and the vaginal incisal mar-
gin, and a T-type tube was placed in the vaginal incision 
for drainage. The vagina was then filled with two pieces of 
iodophor-soaked gauze, a ureteral catheter was placed, and 
the surgery was completed.
Postoperative management and follow-up
Postoperative routine intravenous infusion of antibiot-
ics was performed for 3 to 5 days. The patients were given 
a liquid diet for 6 hours after surgery and a semiliquid diet on 
the following day. The vaginal gauze and ureteral catheter 
were removed 24 hours post-surgically. Vaginal drainage 
generally lasted for approximately 48 to 72 hours. Rou-
tine monitoring of body temperature, hemography, and 
exhaust time were performed. At the 2-month, 6-month 
and 12-month follow-up visits to the general outpatient 
department, general physical examinations, gynecologi-
cal examinations, and pelvic ultrasounds were performed.
Observation indicators
According to the clinical data, the following indicators 
were collected: the location, number, and volume of uterine 
fibroids; operative time; intraoperative blood loss; intra-
Table 1. Demographics of 138 women who underwent vaginal 
myomectomy
Characteristics of patients
Mean age, years ± SD 39.6 ± 11.5
Nulliparous, n (%) 10 (7.2)
Parity, median (range) 1 (0–4)
Previous surgery, n (%)
Previous cesarean section 13 (9.4)
Oophorocystectomy 5 (3.6)
Adnexectomy 2 (1.4)
Tubal ligation 2 (1.4)
Laparotomic myomectomy 1 (7.2)
Appendectomy 3 (2.2)
Symptomatic uterine fibroids, n (%)
Menorrhagia 24 (17.4)
Menostaxis 12 (8.7)
Frequent micturition Symptoms of bladder compression 5 (3.6)
Dysmenorrhea 2 (1.4)
Rapid myoma growth 3 (2.2)
619
Yinghan Chen et al., Clinical evaluation of transvaginal myomectomy surgery: a retrospective study of 138 cases
www. journals.viamedica.pl/ginekologia_polska
operative and postoperative complications; postoperative 
morbidity; length of postoperative hospital stay; and post-
operative fever. Fever was defined as temperature increasing 
to greater than 38°C on two occasions at least 6 hrs apart 
within 24 hrs, commencing 24 hrs after surgery.
Statistical analysis
Statistical analysis was performed using SPSS software, 
version 16 (SPSS Inc. Chicago, IL, USA). The results are ex-
pressed as the mean ± standard deviation.
RESULTS
Characteristics of uterine fibroids 
The characteristics of uterine fibroids in the 138 cases 
of transvaginal myomectomy are shown in Table 2. Greater 
than half of the cases (60.9%) had multiple fibroids. Of these 
cases, 8 had greater than 5 fibroids, and the greatest num-
ber of fibroids removed in one case was 13. Most cases 
(85.5%) had fibroids in the uterine body: 12 cases had cer-
vical fibroids, and 8 cases had broad ligament fibroids. In 
two-thirds of cases (66.7%), the maximum fibroid diameter 
was between 5 and 10 cm, and the largest fibroid removed 
had a diameter of 12 cm.
Perioperative performance data
All 138 cases were successfully completed, with no 
adjacent organ injury or other intraoperative complica-
tions. Perioperative performance data are summarized in 
Table 3. No postoperative complications occurred. Postop-
erative analgesia was considered routine for the transvagi-
nal myomectomy procedure. Postoperative pathological 
examinations revealed uterine fibroids.
Postoperative morbidity: Twelve patients had postop-
erative temperatures greater than 38°C, and the postopera-
tive morbidity rate was 8.7%. All patients underwent blood 
culture and drug susceptibility tests, and Escherichia coli 
was detected in the cultures of two patients. The symptoms 
of ten patients resolved 4 to 6 days after combined treat-
ment with antibiotics and traditional Chinese medicines 
that promote blood circulation and reverse blood stasis. The 
two other patients developed postoperative uterine and 
pelvic abscesses, which were treated with interventional 
ultrasound-guided puncture and pus aspiration. No other 
complications occurred after antibiotic treatment. All pa-
tients with fever were treated with early surgery. The opera-
tive time was a minimum of 1.5 hours.
Prognosis
The mean time to follow-up with patients was 
9.0 ± 2.2 months (3–12 months). There were 43 patients that 
underwent surgery due to menometrorrhagia, menostaxis, 
frequent urination due to bladder compression, or lower ab-
dominal pain. All symptoms were alleviated after surgery; no 
residual fibroids were found on gynecological examination 
or ultrasonography. Postoperative follow-up visits showed 
good healing of the fornix mucosa. Four patients had fertil-
ity requirements. Because contraception was required for 
2 years, and the follow-up period was short, no postopera-
tive pregnancies have been reported.
DISCUSSION
Though transvaginal myomectomy has many benefits 
as mentioned, it is not suitable for all patients who re-
quire myomectomy. However, there is currently no uniform 
standard for indications for transvaginal myomectomy [11]. 
Some scholars have suggested that the size of the uterus 
should not exceed the gravid uterus at 12, 14, or 16 weeks 
Table 2. Characteristics of Myomas
Characteristics of Myomas
Single, n (%) 54 (39.1)
Multiple, n (%)
≤ 5 76 (55.1)
> 5, ≤ 10 6 (4.3)
> 10 2 (1.4)
Corpus myoma, n (%)
Subserosal 47 (34.1)
Intramural 54 (39.1)
Intramural/Subserosal 17 (12.3)
submucous 0
Special position, n (%)
Cervical myoma 11 (8.0)
Cervical/corpus 1 (0.7)
Broad ligament myoma 8 (5.8)
Broad ligament/corpus 0
Myoma size cm ± SD 6.7 ± 1.8
Diameter ≤ 5 cm, n (%) 43 (31.2)
Diameter > 5 cm ≤ 10 cm, n (%) 92 (66.7)
Diameter > 10 cm, n (%) 3 (2.2)
Table 3. Perioperative performance
Characteristic Results
Mean operative time (min ± SD, range) 56.0 ± 17.2 (30–110)
Mean blood loss (mL ± SD, range) 89.2 ± 36.8 (40–300)
Blood transfusion rate (n, %) 1 (0.7)
Mean intestinal function recovery time, 
median days (range) 1 (1–4)
Postoperative fever (n, %) 12 (8.7)
Mean hospitalization after surgery, 
median days (range) 4 (3–10)
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of gestation. Others have suggested that the diameter of 
fibroids should be no more than 7 cm, 10 cm or 11 cm. Still 
others have suggested that the number of fibroids should 
not exceed three, while some scholars believe that there 
should be no restrictions on the number of fibroids. It has 
also been suggested that fibroids in the anterior wall are 
not suitable for transvaginal myomectomy [12–15]. We 
believe that whether transvaginal myomectomy is a suit-
able treatment option depends on the patient’s condi-
tions. The decision to perform transvaginal myomectomy 
is determined based on a comprehensive assessment of 
multiple factors, including size, number, type (subserosal, 
intramural, etc.), and location of fibroids, vaginal condi-
tions, the history of pelvic inflammation, proficiency of 
the surgeon, and the presence of an adnexal mass. Careful 
gynecological examination and ultrasonography are very 
important to determine if the patient is a candidate for this 
procedure. A MRI should be performed before surgery if 
necessary. Adequate preoperative assessment and adher-
ing to strict indications are essential for the success of the 
surgery. Therefore, the incidence of intraoperative and 
postoperative complications can be avoided or reduced, 
and the likelihood of conversion to laparotomy can be 
minimized.
Transvaginal myomectomy has multiple advantages, 
which have been discussed extensively [16, 17]. These 
include advantages in operative time, intraoperative 
blood loss, degree of postoperative pain, postopera-
tive recovery time of intestinal function, average length 
of postoperative hospital stay, medical expenses, and 
aesthetic/psychological effects without abdominal inci-
sions [18]. The results of this study are consistent with 
the general conclusions of previous studies. We believe 
that, compared with laparoscopic surgery, the great-
est advantage of transvaginal myomectomy is that the 
surgeon can perform every step of the operation under 
direct vision, which is more accurate, safe and expedient 
than under microscopic view. This is true especially when 
the fibroids are large and buried deeply in the uterus. In 
the case of a transvaginal approach, conventional lay-
ered sutures can be performed on deep uterine muscle 
wounds, which can improve the reliability of repairing 
large uterine defects and can compensate for the defi-
ciency of the laparoscopic approach in this area. In addi-
tion, because transvaginal myomectomy does not require 
expensive and complex equipment, it is more suitable for 
economically underdeveloped areas.
However, transvaginal myomectomy has not been as 
widely practiced as laparoscopic myomectomy, mainly due 
to the technical difficulties of transvaginal operations, in-
cluding limited operating space, restricted field of view and 
concerns about the injury risk of adjacent organs [17, 19]. 
The key to this procedure is eversion of the uterus; there-
fore, preoperative examination should determine the loca-
tion of the major fibroids. If a fibroid protrudes from the 
anterior wall, it is easy to evert the uterus from the anterior 
fornix. Otherwise, it should be everted from the posterior 
fornix. When the volume of the uterus is large, or large 
fibroids are present, it is often necessary to gradually open 
the fibroid pseudocapsule while outwardly pulling the 
uterus. The fibroid is separated until a tenaculum can be 
used to grasp and remove it. Alternatively, the fibroid 
can be morcellated while being stripped to reduce the 
fibroid volume until the fibroid can be fully removed. In 
addition, the inherently narrow field of vaginal surgery 
does not have the magnification effect of laparoscopic 
surgery; thus, vaginal surgery is not conducive to extensive 
learning and training.
Postoperative fever is a common complication of vagi-
nal myomectomy. Compared with laparoscopic surgery, 
vaginal myomectomy has a higher postoperative morbid-
ity rate [11, 20]. In this group of patients, the body tem-
peratures of 12 patients exceeded 38°C, and two patients 
developed postoperative uterine and pelvic abscesses, 
which were relieved by interventional ultrasound-guided 
puncture and pus aspiration, followed by 4–6 days of 
combined treatment using antibiotics and traditional 
Chinese medicines that increase blood circulation and 
reverse blood stasis. The reason for the high incidence 
of fever after transvaginal myomectomy is related to the 
fact that the uterus is a muscular organ with an abun-
dant blood supply [21]. Enucleation of uterine fibroids 
is a process in which a large number of blood vessels are 
exposed, and the chance of infection is increased when 
the uterus, with its exposed blood vessels, remains for 
a long time in the bacterial environment of the vagina. 
In this study, all cases of postoperative fever occurred in 
the early study period. Since preoperative vaginal prepa-
ration was emphasized, the occurrence of postoperative 
fever was significantly reduced after adequate and strict 
vaginal disinfection. In addition, the operative time of 
patients with postoperative fever was close to or more 
than 1.5 hours in this study. With increasing surgical pro-
ficiency, the operation time was shortened, thus reduc-
ing the uterine exposure time. Therefore, the duration 
of uterine congestion caused by uterine eversion was 
minimized, and the occurrence of postoperative fever 
was also reduced. 
In summary, transvaginal myomectomy has its own 
independent indications and numerous advantages, and 
it is a useful supplement to the transabdominal operation. 
As long as the surgeon is proficient in transvaginal surgical 
skills and is familiar with the surgical indications, it is safe 
to perform transvaginal myomectomy.
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